Picture of Arrowhead Pharmaceuticals logo

ARWR — Arrowhead Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Arrowhead Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

* Arrowhead Pharmaceuticals Inc  ARWR.OQ  reported a
quarterly
adjusted loss of $1.37​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of $-1.02.  The mean expectation of
fifteen analysts for the quarter was for a loss of $1.05 per
share. Wall Street expected results to range from $-1.57 to -1
cents per share.
    * Reported revenue was zero​; analysts expected $63.82
million. 
    * Arrowhead Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $1.37​.
    * The company reported a quarterly loss of $170.54 million.
    * Arrowhead Pharmaceuticals Inc shares had fallen by 3.0%
this
quarter and lost 38.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Arrowhead
Pharmaceuticals Inc is $50.50 
This summary was machine generated from LSEG data November 26 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.05          -1.37          Missed
 Jun. 30 2024      -0.55          -1.38          Missed
 Mar. 31 2024      -0.16          -1.02          Missed
 Dec. 31 2023      -0.82          -1.24          Missed

Recent news on Arrowhead Pharmaceuticals

See all news